SAN DIEGO – March 3, 2006 – Verus Pharmaceuticals, Inc., a pediatric-oriented specialty pharmaceutical company, today announced it will donate 5,000 Twinject® demonstrator devices for Anaphylaxis Day activities on March 5 during the 2006 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. Anaphylaxis Day aims to educate physicians, health care professionals and the public about anaphylaxis, a severe, life-threatening systemic allergic reaction. Twinject, a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions, is the only available product approved by the FDA that contains two doses of epinephrine in a single, compact device. On March 7, Mathew Varghese, M.D., currently a Research Fellow at the University of South Florida, will present a poster entitled "Factors Affecting the Use of Automatic Epinephrine Injectors", regarding a study designed to assess the incidence of anaphylactic episodes requiring more than one dose of epinephrine. The study was co-authored by Phillip L. Lieberman, M.D., Clinical Professor of Medicine and Pediatrics in the Department of Medicine and Pediatrics, Divisions of Allergy and Immunology at the University of Tennessee Center for the Health Sciences.

"We are honored to work with the AAAAI to increase awareness of anaphylaxis and to expand education regarding the proper diagnosis and treatment protocol for this life-threatening condition," said Robert W. Keith, President and Chief Operating Officer, Verus Pharmaceuticals. "The dual-dose capability of Twinject addresses a significant unmet medical need and may save lives. Published studies have demonstrated that more than one dose of epinephrine may be required in many situations to properly address the allergic reaction, with the second dose often needed within 5-10 minutes after the first. As such, we are excited to donate Twinject demonstrators for Anaphylaxis Day to promote hands-on training and for the Anaphylaxis Tool Kits that will be made available during the conference."

About Anaphylaxis

Anaphylaxis is a severe, life-threatening systemic allergic reaction triggered by exposure to one or more various antigens, including foods, insect stings, drugs, and latex products. Up to 43 million people in the U.S. alone are at risk for anaphylactic episodes, and underlying incidence rates are expected to continue increasing in future years. Up to eight percent of children have food allergies, with allergies to peanuts and tree nuts among children having doubled in the past five years. The timing, location, pattern (including onset, severity and length) and specific treatment requirements for each future episode cannot be predicted in advance. As such, all at risk patients need to be fully prepared at all times for these unpredictable episodes.

About Twinject

Twinject Auto-Injector (epinephrine injection, USP 1:1000) is the only available product approved by the FDA that contains two doses of epinephrine in a single, compact device. This is an important feature, as published studies indicate that more than one dose of epinephrine may be required for one in three patients to properly address the allergic reaction, with the second dose often needed within 5-10 minutes after the first. More information about anaphylaxis and Twinject is available on the company’s Twinject website at www.twinject.com

About Verus

Verus Pharmaceuticals is dedicated to improving the lives of children and those who care for them. Verus is building a portfolio of products for the unmet medical needs of children through acquisitions and alliances, with an initial focus on the treatment of asthma, allergies, and related diseases and conditions. Verus is differentiated by its pediatric orientation and its strong financial position and experienced management team, which allows the company to capitalize on an extensive network to build its product portfolio and pursue complementary transactions. The company’s rigorous, disciplined approach to strategic decision-making and core competencies in development and commercialization is expected to provide significant value to its partners. More information about Verus is available on the company’s corporate website at www.veruspharm.com

Verus™ and Twinject® are trademarks of Verus Pharmaceuticals, Inc.

Forward-Looking Statements

Verus Pharmaceuticals cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Verus that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Verus’ business including, without limitation, statements about: its ability to identify appropriate acquisition, licensing, or co-development and/or promotion candidates in the future or be able to take advantage of the opportunities it identifies; difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products; unexpected performance or side effects of its products that could delay or prevent development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and Verus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.